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Background and Purpose. We investigated the potency of Peroxisome Proliferators-Activated Receptors (PPARs) α, β/δ,a n dγ
agonists to modulate Transforming Growth Factor-β1( T G F - β1-) induced collagen production or changes in Tissue Inhibitor of
Matrix Metalloproteinase- (TIMP-) 1/Matrix Metalloproteinase (MMP) balance in rat chondrocytes embedded in alginate beads.
Experimental Approach. Collagen production was evaluated by quantitative Sirius red staining, while TIMP-1 protein levels and
global MMP (-1, -2, -3, -7, and -9) or speciﬁc MMP-13 activities were measured by ELISA and ﬂuorigenic assays in culture
media, respectively. Levels of mRNA for type II collagen, TIMP-1, and MMP-3 & 13 were quantiﬁed by real-time PCR. Key
Results.T G F - β1 increased collagen deposition and type II collagen mRNA levels, while inducing TIMP-1 mRNA and protein
expression. In contrast, it decreased global MMP or speciﬁc MMP-13 activities, while decreasing MMP-3 or MMP-13 mRNA
levels. PPAR agonists reduced most of the eﬀects of TGF-β1 on changes in collagen metabolism and TIMP-1/MMP balance in rat
inaPPAR-dependentmanner,exceptedforWy14643onMMPactivities.ConclusionsandImplications.PPARagonistsreduceTGF-
β1-modulated ECM turnover and inhibit chondrocyte activities crucial for collagen biosynthesis, and display a diﬀerent inhibitory
proﬁle depending on selectivity for PPAR isotypes.
1.Introduction
Articular cartilage is an avascular,aneuronal, and alymphatic
connective tissue designed to distribute mechanical load,
and provide a wear-resistant surface to the articular joints
[1]. These biomechanical properties are supported by a
specializedextracellularmatrixwhichismaintainedbychon-
drocytes, the unique cellular component of hyaline cartilage,
under normal conditions of low turnover. Disruption of
chondrocyte-matrix associations and alteration of metabolic
responses in chondrocytes are thought to contribute to
the pathogenesis of osteoarthritis [1], especially when the
biosynthetic anabolic activity is unable to keep pace with
the degradative catabolic activity [2]. Indeed, key patho-
logical ﬁndings of osteoarthritic cartilage include excessive
production of matrix degrading proteinases and proinﬂam-
matory cytokines, enhanced apoptosis, alteration of the
chondrocytic phenotype, secondary osteophytes formation,
decreased biosynthesis of cartilage speciﬁc molecules, and/or
defective responses to growth factors [1]. The imbalance
betweenchondrocytefunctionsisthereforethoughttoreﬂect
the imbalance between catabolic cytokines and anabolic
growth factors into diseased joints [3].
Transforming Growth Factor- (TGF-) β is a multifunc-
tional growth factor [4]. In hyaline cartilage, TGF-β is pro-
duced in a latent form that does not activate TGF-β receptors
but behaves as a great modulator of cartilage metabolism in
its active form. Thus, it is a potent stimulator of chondrocyte
proliferation [5] and diﬀerentiation [6] which stimulates
cartilage-speciﬁc type II collagen or aggrecan synthesis2 PPAR Research
[7–10] and modulates matrix metalloproteases activities by
increasingsynthesisoftheirnaturaltissueinhibitors[11,12].
TGF-β1 may have a multifaceted physiopathological role in
joint diseases depending variably on cartilage protection,
bone remodelling and synovial expression suggesting the
involvement of TGF-β1 in the evolution of osteoarthritis
disease.
Peroxisome Proliferators-Activated receptors (PPARs)
are ligand-activated nuclear transcription factors belonging
to the nuclear hormone receptor superfamily [13]. PPAR
regulated genes involved in glucose and lipid homeosta-
sis by binding to Peroxisome Proliferators-Response Ele-
ments (PPRE) located in their promoter. Three subtypes
are encoded by separate genes, PPAR α,P P A Rβ/δ,a n d
PPAR γ [14]. PPAR ligands diﬀer greatly in their binding
aﬃnity between endogenous and synthetic agonists. Thus,
arachidonic acid metabolites, such as leukotriene B4 for
PPAR α, prostaglandin I2 for PPAR β/δ, or 15-deoxy-
prostaglandin J2 (15d-PGJ2)f o rP P A Rγ [15], are much
less eﬀective than pyrixin acid (Wy14643) or ﬁbrates for
PPAR α, GW501516 for PPAR β/δ, or thiazolidinediones
for PPAR γ [16]. PPAR activation is associated with key
functions including oxidation of fatty acids in liver (PPAR
α) and skeletal muscle (PPAR β/δ)o rd i ﬀerentiation of
adipocytes in adipose tissue (PPAR γ), opening insight to
the treatment of metabolic syndrome and cardiovascular
diseases [17]. PPARs are also implied in the control of the
inﬂammatory response [18] and epithelial repair pathways,
with a foremost contribution of PPAR β/δ and PPAR γ to
skin wound healing and liver or kidney ﬁbrosis, respec-
tively [19]. Their activation is associated with a reduced
secretion of inﬂammatory cytokines and a lower activation
of matrix metalloproteases [20] in articular cell culture or
experimental arthropathy [21, 22]. PPAR agonists can also
repress the synthesis of extracellular matrix components
in quite a lot of cell types, such as collagen synthesis
by thiazolidinediones in mesangial cells from diabetic rats
[23] and Wy14643 in hepatic stellate cells from rats with
cholestatic liver ﬁbrosis [24]. Likewise, ﬁbronectin expres-
sion is inhibited by pioglitazone in human kidney ﬁbroblasts
[25].
We investigated the ability of selective agonists of the
three PPAR isotypes to aﬀect TGF-β1-induced changes
in collagen synthesis and TIMP-1/MMPs’ balance in rat
chondrocytes. In our culture system, the stimulatory eﬀect
of TGF-β1 on collagen deposition or type II collagen mRNA
expression was dramatically reduced by all PPAR agonists.
Wy14643 was solely associated with inhibition of basal
MMP-3 & -13 mRNA expression and basal global MMP (-
1, -2, -3, -7, and -9) or speciﬁc MMP-13 activities whereas all
PPAR agonists reduced the stimulatory eﬀect of TGF-β1o n
TIMP-1. Our data demonstrates that PPAR agonists reduce
TGF-β1-induced responses in chondrocytes and may favour
an altered repair capacity of cartilage in response to growth
factors. When considering the important role of TGF-β1i n
cartilage repair, in vivo studies become obvious to assess
whether the antianabolic eﬀe c to fP P A Ra g o n i s t sc o u l db e
counterbalanced by their potency to reduce synovitis and/or
prevent osteophyte formation.
2.MaterialsandMethods
2.1. Chondrocyte Isolation and Culture in Alginate. Normal
articularcartilagewasobtainedfromfemoralheadsofWistar
male rats (150–175g; Charles River, L’Arbresle, France)
killed under dissociative anesthesia (ketamine (M´ erial, Lyon,
France) and acepromazine (Sanoﬁ Sant´ e Animale, Libourne,
France)) in accordance with national animal care guidelines,
after approval by our internal ethics committee. Chondro-
cytes were isolated by sequential enzymatic digestion of head
caps using 0.15% pronase and 0.2% collagenase B (Roche
Molecular Biochemicals, Meylan, France), then washed two
times in phosphate buﬀered saline (PBS) and cultured up
to conﬂuence in 75cm2 ﬂasks at 37◦C in a humidiﬁed
atmosphere containing 5% CO2. The medium used was
Dulbecco’s Modiﬁed Eagle Medium (DMEM) (Invitrogen,
Cergy Pontoise, France) supplemented with L-glutamine
(2mM), penicillin-streptomycin (50μg/mL), amphotericin
B( 0 . 5 μg/mL), and 10%(v/v) heat-inactivated fetal calf
serum (FCS) (Invitrogen, Cergy Pontoise, France). After
two passages, chondrocytes were encapsulated in alginate
beads according to Ballock et al. [26]. Brieﬂy, the cells were
suspended in a 1.2% sterile solution of medium viscosity
alginate (Sigma-Aldrich, Saint Quentin Fallavier, France) at
a concentration of 5.106 cells per mL and dispensed drop-
wise into a 102mM CaCl2 solution via a 22-gauge needle
attached to a syringe. After instantaneous polymerisation,
beads were allowed to further their polymerization for 15
minutes in CaCl2 solution before three washes in sterile
0.15M NaCl solution, followed by two washes in complete
culture medium. The beads were maintained in complete
culture medium for seven days at 37◦C in a humidiﬁed
atmosphere of 5% CO2 before experiments.
2.2. Study Design. After seven days of culture, beads were
transferred into culture medium containing 1%(v/v) FCS
and were maintained under low-FCS conditions throughout
the experiments.
In a ﬁrst set of experiments, the eﬀect of selected concen-
trations of selective PPAR agonists was studied on TGF-β1-
induced (10ng/mL; Peprotech Tebu, Le Perrey en Yvelines,
France) changes in collagen production and TIMP-1/MMPs
balance. The selective PPAR agonists used were Wy14643
(100μM, Calbiochem, Meudon, France) as PPAR α agonists,
GW501516 (100nM, Alexis Biochemicals, Paris, France)
as PPAR β/δ agonists, and rosiglitazone (10μM, Cayman
Chemical, Ann Arbor, MI) as PPAR γ agonists. Agonists
were added 2 hours before TGF-β1 and biological responses
were studied 48 hours (gene expression) or 72 hours (matrix
metabolism) after addition of TGF-β1. PPAR ligands were
dissolved in dimethyl sulfoxide (DMSO) (Sigma-Aldrich)
and used at a ﬁnal concentration of less than 0.1% in culture
medium.
In a second set of experiments, control experiments were
performed in the presence of speciﬁc antagonists (GW6471
(10μM; Tocris Bioscience, Paris, France) for PPAR α and
GW9662(10μM;CaymanChemical)forPPARγ)toevaluate
theinvolvement ofPPARisotypeintheanti-TGF-β1pot e ncy
of PPAR agonists on collagen deposition, type II collagenPPAR Research 3
mRNA expression, and global MMP (-1, -2, -3, -7, and -9).
PPAR ligands were dissolved in DMSO and used at a ﬁnal
concentration of less than 0.2% in culture medium.
2.3. DNA Measurement Assay. Cells were incubated for
24h to 72h at 37◦C in the presence or absence of
TGF-β1 and/or PPAR agonists (added 2h before TGF-
β1when coincubated) in low-FCS (1%) culture medium.
After stimulation, alginate beads were dissolved in citrate-
EDTA buﬀer (55mM/50mM; pH 7.6) for 10min at 37◦C,
and then centrifuged at 10000rpm for 15 seconds. The
supernatants were discarded and the pellets were washed
5 times with PBS. Then the pellets were suspended in
100μL of Hoechst buﬀer (10mM TRIS, 1mM EDTA, and
0.1M of NaCl, pH 7.4) before 5 series of freezing (nitrogen
liquid)/defreezing (60◦C, 5min) for lysing cells. The samples
were mixed with 2ml of Hoechst solution (0.1μg/mL in
ﬁnal concentration, Hoechst 33528 FluoProbes, Interchim.
France) and the measurement of absorbance at 456nm on a
ﬂuorescence spectrophotometer (HITACHI F-2000, Science
Tec., Courtaboeuf, Les Ulis, France) was used to calculate the
amountsoftotalDNAinthesamplesusingcalfthymusDNA
(0.05–0.5μg/mL)asastandardandcell-freealginatebeadsas
a blank.
2.4. Regional Localization of Collagens in Beads. After stim-
ulation with TGF-β1, in the presence or absence of PPAR
agonists and/or PPAR antagonists, alginate beads were ﬁxed
for 4h at 20◦C in a 4% paraformaldehyde solution (pH 7.4)
(Sigma-Aldrich) containing 100mM sodium cacodylate and
10mM CaCl2, then washed overnight in 100mM sodium
cacodylate buﬀer containing 50mM BaCl2. Graded solutions
ofethanolwereusedtodehydratesamples,thenembeddedin
paraﬃn and cut into sections (5μm thickness), before stain-
ing with Sirius red (Direct Red 80, Sigma Aldrich) (0.1%w/v
in picric acid) for the visualization of collagen synthesis.
Sections(n = 5beadspercondition)wereobservedatamag-
niﬁcation 100x or 400x with a photonic microscope (Nikon
type 104, Tokyo, Japan) and staining intensity was analyzed
using NIH Image software (http://rsb.info.nih.gov/).
2.5. Assay for Matrix Metalloproteases Activities. After stim-
ulation with TGF-β1, in the presence or absence of PPAR
agonists, global MMP activities were measured in culture
supernatants using ﬂuorogenic substrates. Latent MMP
were activated by adding 50μL of 4-aminophenylmercuric
acetate (APMA, 1.5mM in Tris-HCl (50mM, pH 7.5)
reaction buﬀer containing 1.5mM NaCl and 5mM CaCl2)
to 50μL of culture supernatant. Then, 50μL of the ﬂu-
orogenic MMP (-1, -2, -3, -7, and -9) substrate “DNP-
Pro-Leu-Gly-Leu-Trp-Ala-D-Arg-NH2”( λexcitation 280nm,
λemission 360nm; Calbiochem, La Jolla, CA) or of the MMP-
13 substrate “MCA-Pro-Cha-Gly-Nva-His-Ala-Dpa-NH2”
(λexcitation 325nm, λemission 393nm; Calbiochem, La Jolla,
CA) were added to a ﬁnal concentration of 30μMa n d
60μM, respectively. After 4h of incubation in darkness at
37◦C in a humidiﬁed atmosphere of 5% CO2, MMP-induced
cleavage of substrates was measured with a Fluostar Optima
spectroﬂuorimeter (BMG Labtechnologies, Champigny sur
Marne, France) at emission wavelengths of 360nm for total
MMP and 393nm for MMP-13.
2.6. Assay for Tissue Inhibitor of Metalloproteinase-1 (TIMP-
1). TIMP-1 levels were assessed in the same culture super-
natants as for MMP activities using a commercially available
rat enzyme-linked immunosorbent assay (Quantikine, R&D
Systems, Minneapolis, MN) according to the manufac-
turer’s instructions. This assay showed no signiﬁcant cross-
reactivity with other TIMPs and the limit of detection was
37.5pg/mL.
2.7. RNA Extraction and Real-Time Polymerase Chain Reac-
tion. Alginate beads were dissolved in citrate-EDTA buﬀer
(55mM/50mM; pH 7.6) for 10min at 37◦C, and then
centrifuged at 10000rpm for 15 seconds. The supernatants
were discarded and the pellets were washed 5 times with
PBS before extraction of total RNA using RNeasy minikit
(Qiagen, Valencia, CA). Total RNA (500ng) were reverse
transcribed in a ﬁnal volume of 50μL containing 10μLo f5 X
First Strand Buﬀer, 20μM hexanucleotides random primers,
1μL of Recombinant Ribonuclease Inhibitor (RNA-se OUT
40 U/μL), 2μLo fd N T P( 5 m M ) ,a n d1 μLo fM o l o n e y
Murine Leukemia Virus (M-MLV; 200U/μL) (Invitrogen)
for 90min at 37◦C. To quantify type II collagen, MMP-3
& -13, and TIMP-1 mRNAs expression, real-time PCR was
performed using the Lightcycler Technology (Roche Molec-
ular Biochemicals) and the SYBRgreen master mix system
(Qiagen,Courtaboeuf,France).Thesequencesoftheprimers
used and corresponding product lengths are summarized in
Table 1. The transcript level of the housekeeping gene RP29
was determined for each sample; data are expressed as the
normalized ratio of mRNA level of each gene of interest over
the RP29 gene.
2.8. Statistical Analysis. Data are expressed as mean ±
standard error of the mean (SEM) of 3 to 10 values
obtained from 1 to 3 separate experiments. Comparisons
were made by ANOVA, followed by Fisher’s protected least
signiﬁcant diﬀerence test using StatView 5.0 software (SAS
Institute, Cary, NC). Statistically signiﬁcant diﬀerences from
the control are indicated as ∗P<. 05, from TGF-β1-treated
cellsas #P< . 05,andfrom“TGF-β1+PPARligands”-treated
cells as §P<. 05.
3. Results
3.1. Eﬀects of TGF-β1 and PPAR Agonists on Cell Viability
and Proliferation. In rat chondrocyte beads, TGF-β1 did
not signiﬁcantly increase cell proliferation as time went on
(Figure 1(a)).WeobservedpreviouslythatWy14643behaved
as a selective PPAR α agonist at 100μM, GW501516 as a
selective PPAR β/δ agonist at 100nM, and rosiglitazone as
a selective PPAR γ agonist [10]. In the same conditions of
selectivity, PPAR agonists were found to be nontoxic for
chondrocytes after 72h of cell culture, in the presence or the
absence of TGF-β1( Figure 1(b)).4 PPAR Research
Table 1: Primers used for real-time PCR and corresponding product lengths.
Target
genes Primer sequence Forward Primer sequence Reverse Tm (◦C) Length (Pb)
RP 29 5
 -AAG ATG GGT CAC CAG CAG CTC
TAC TG-3
 
5
 -AGA CGC GGC AAG AGC GAG
AA-3
  59 67
Type II
Collagen 5
 -TCC CTC TGG TTC TGA TGG TC-3
  5’-CTC TGT CTC CAG ATG CAC CA-3
  59 161
TIMP-1 5
 -TCC CCA GAA ATC ATC GAG AC-3
  5
 -TCA GAT TAT GCC AGG GAA CC-3
  61 159
MMP-3 5
 -GCT CAT CCT ACC CAT TGC AT-3
  5
 -GCT TGT GCA TCA GCT CCA TA-3
  58 219
MMP-13 5
 -AGG CCT TCA GAA AAG CCT TC-3
  5
 -GAG CTG CTT GTC CAG GTT TC-3
  58 226
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Figure 1: Eﬀects of selective PPAR agonists on cell prolifera-
tion in rat chondrocytes stimulated with TGF-β1. Chondrocytes,
embedded in alginate beads (5.104 cells per bead), were exposed to
Wy14643 (100μM), GW501516 (100nM), or rosiglitazone (10μM)
for 2h before stimulation with TGF-β1 (10ng/mL), in the presence
or absence of PPAR agonists, for 72h. Levels of total DNA were
measured by Hoechst assay. (a) Time course eﬀect of TGF-β1; (b)
eﬀect of PPAR agonists in presence of TGF-β1. Data are expressed
as mean ± SEM.
3.2. Eﬀects of PPAR Agonists on TGF-β1-Induced Changes
in Metabolism of Collagens. TGF-β1 increased the intensity
of Sirius red staining by 8.2-fold (Figures 2(a), 2(b),a n d
2(c)), while increasing the mRNA level of type II collagen
by 4.5-fold (Figure 3). As expected from our experimental
conditions, Sirius red staining was mainly localized around
chondrocytes and highlighted the lack of any collagen ﬁbers
(Figures 2(a) and 2(b)).
PPAR agonists suppressed the basal staining for collagens
or procollagens and reduced almost completely the TGF-
β1-induced increase in staining intensity (Figures 2(b)
and 2(c)). Accordingly, the stimulatory eﬀect of TGF-β1
on type II collagen expression was completely suppressed
by all agonists, with a maximal inhibitory potency for
rosiglitazone (Figure 3). However, each agonist decreased
the basal expression of type II collagen reaching an 80%
inhibition for rosiglitazone (Figure 3).
3.3. Eﬀects of PPARs Agonists on TGF-β1-Induced Changes
in MMP/TIMP-1 Balance. TGF-β1 decreased global MMP
and MMP-13 activities by 66% and by 19%, respectively,
(Figures 4(a) and 4(b)), while increasing TIMP-1 levels
by 75% (Figure 4(c)). Consistently, the levels of mRNA
for MMP-3 and -13 were reduced by 50% and by 10%,
respectively, whereas those for TIMP-1 were upregulated by
65% (Table 2).
In the presence of PPAR agonists, the inhibitory potency
of TGF-β1 on MMP activities (Figures 4(a) and 4(b))
and mRNA levels (Table 2)w a sr e v e r s e dc o m p l e t e l yb y
rosiglitazone and GW501516, while being unaﬀected by
Wy14643. However, the basal MMP activities were decreased
signiﬁcantly by Wy14643 (Figures 4(a) and 4(b)), as well as
the basal mRNA levels for MMP-3 and MMP-13 (Table 2).
The stimulatory eﬀect of TGF-β1o nT I M P - 1p r o t e i n
(Figure 4(c))a n dm R N A( Table 2) levels was inhibited by
all PPAR agonists with a major inhibitory potency for
rosiglitazone and Wy14643. However, Wy14643 reduced the
b a s a ll e v e l so fT I M P - 1p r o t e i na n dm R N Ab y4 0 %a n db y
51%, respectively, (Figure 4(c); Table 2).
3.4.ReversionoftheAntianabolicPotencyofthePPARAgonists
by Selective Antagonists. Preliminary experiments using the
MTT assay showed no loss of viability of rat chondrocytes
exposed to PPAR agonists or PPAR antagonists, alone or inPPAR Research 5
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Figure 2: Eﬀects of selective PPAR agonists on TGF-β1-induced collagens metabolism in rat chondrocytes. Chondrocytes, embedded in
alginate beads (5.104 cells per bead), were exposed to Wy14643 (100μM), GW501516 (100nM), or rosiglitazone (10μM) for 2h before
stimulation with TGF-β1 (10ng/mL), in the presence or absence of PPAR agonists for 72h. (a) Representative sections of Sirius red staining
of beads (n = 5, G: 100X); (b) Representative map of Sirius red staining intensity (n = 5); (c) Mean overall quantiﬁcation of Sirius red
staining on beads sections (n = 5). Data were expressed as mean ± SEM and statistically signiﬁcant diﬀerences from the control were
indicated as ∗P<. 05 and from TGF-β1-treated cells as #P<. 05.
combination, in the concentration range tested (data not
shown).
3.5. Eﬀects on Collagen Metabolism
3.5.1. Eﬀects on Collagen Deposition. In our experimental
condition (0.2% DMSO instead of 0.1%), the stimulatory
eﬀect of TGF-β1 (4.5-fold increase) on collagen deposition
in the extracellular matrix (cell-associated matrix) was not
aﬀected by the PPARα antagonist GW6471 but was potenti-
ated by the PPARγ antagonist GW9662 (6.8-fold increase)
(Figures 5(a) and 5(b)). As observed previously, TGF-β1-
induced collagens deposition was dramatically reduced by
all PPAR agonists with a maximal inhibitory potency with
rosiglitazone. In the presence of GW6471, the inhibitory
potency of Wy14643 was completely relieved whereas those
of GW501516 and rosiglitazone remained unchanged (Fig-
ures 5(a) and 5(b)). However, the inhibitory potency of
rosiglitazone and GW501516 was totally suppressed by
GW9662 whereas that of Wy14643 was not (Figures 5(a) and
5(b)).
3.5.2. Eﬀects on Type II Collagen mRNA Expression. As for
collagen deposition, the stimulatory eﬀect of TGF-β1o n
the mRNA level of type II collagen (5-fold increase) was
not signiﬁcantly aﬀected by the PPARα antagonist GW6471
but was potentiated by the PPARγ antagonist GW9662 (8-
fold increase) (Figure 6). Control experiments showed that
GW6471 did not modify the basal level of type II collagen
mRNA (data not shown), which was reduced by all PPAR6 PPAR Research
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Figure 3: Eﬀects of selective PPAR agonists on TGF-β1-induced
type II collagen mRNA expression in rat chondrocytes. Chon-
drocytes, embedded in alginate beads (5.104 cells per bead),
were exposed to Wy14643 (100μM), GW501516 (100nM), or
rosiglitazone (10μM) for 2h before stimulation with TGF-β1
(10ng/mL), in the presence or absence of PPAR agonists for 48h.
Normalized mRNA levels of type II collagen were quantiﬁed by
real-time PCR (n = 4). Data were expressed as mean ± SEM and
statistically signiﬁcant diﬀerences from the control were indicated
as ∗P<. 05 and from TGF-β1-treated cells as #P<. 05.
agonists but markedly enhanced (2.4-fold) by GW9662
(Figure 6). In these conditions, TGF-β1-induced type II
collagen expression was reduced by all PPAR agonists (from
75% for GW501516 to below basal level for rosiglitazone). In
the presence of GW6471, the inhibitory potency of Wy14643
was relieved whereas that of GW501516 and rosiglitazone
remained unaﬀected (Figure 6). However, the inhibitory
potency of rosiglitazone and GW501516 was relieved in
the presence of GW9662 whereas that of Wy14643 was
accentuated.
3.5.3. Eﬀects on Global MMP (-1, -2, -3, -7, and -9). As
shown in Figure 7,T G F - β1-induced a loss of global MMP
(-1, -2, -3, -7, and -9) activities which was reduced in
our new experimental conditions (0.2% DMSO instead of
0.1%) but was signiﬁcantly aﬀected neither by GW9662
nor by GW6471. In these experimental conditions, the
inhibitory eﬀect of TGF-β1 on global MMP (-1, -2, -3, -7,
and -9) activities was relieved by rosiglitazone, while being
partly inhibited by GW501516 but moderately potentiated
by Wy14643 (Figure 7). The anti-TGF-β1p o t e n c yo fr o s i g l i -
tazone was decreased selectively by GW9662. In contrast,
that of GW501516 was relieved neither by GW6471 nor by
GW9662,whilethatofWy14643wasmoderatelyaccentuated
(Figure 7). Taken all together, these data demonstrate the
contribution of PPAR in the inhibitory potency of all
PPAR agonists, excepted for Wy104643 which probably
inhibited global MMP activities through PPAR-independent
mechanism pathways.
Table 2: Eﬀects of selective PPAR agonists on TGF-β1-induced
changes in MMPs and TIMP-1 genes expression in rat chondro-
cytes. Chondrocytes, embedded in alginate beads (5.104 cells per
bead), were exposed to Wy14643 (100μM), GW501516 (100nM),
or rosiglitazone (10μM) for 2h before stimulation with TGF-
β1 (10ng/mL), in the presence or absence of PPAR agonists, for
48h. Normalized mRNA levels of MMP-3, MMP-13, and TIMP-1
quantiﬁed by real-time PCR (n = 4). Data are expressed as mean
± SEM. Statistically signiﬁcant diﬀerences from the control are
indicated as ∗P< . 05, and from TGF-β1-treated cells as #P<. 05.
PPAR agonists Genes/RP29
MMP-3 MMP-13 TIMP-1
None
w/o TGFβl1 .00 ±0.04 1.00 ±0.03 1.00 ±0.06
+T G F βl0 .45 ±0.04∗ 0.89 ±0.02 1.65 ±0.07∗
Wy14643
w/o TGFβl0 .54 ±0.01∗ 0.13 ±0.03∗ 0.49 ±0.04∗
+T G F βl0 .56 ±0.06 0.44 ±0.10# 0.71 ±0.21#
GW501516
w/o TGFβl1 .28 ±0.08 1.52 ±0.12∗ 1.10 ±0.14
+T G F βl1 .45 ±0.07# 1.68 ±0.05# 1.38 ±0.05
Rosiglitazone
w/o TGFβl1 .24 ±0.20 1.24 ±0.02 0.76 ±0.03∗
+T G F βl1 .40 ±0.18# 1.44 ±0.03# 1.00 ±0.14#
4. Discussion
In the presence of PPAR agonists, the basal expression of
type II collagen was decreased, in good accordance with
their ability to prevent kidney [23, 27]o rl i v e r[ 24]ﬁ b r o s i s .
More importantly, the stimulatory eﬀect of TGF-β1o ni t s
expressionwasreducedalmostcompletely.Siriusredstaining
followed the same variation, suggesting that transcriptional
inhibition by PPAR agonists resulted in decreased synthesis
of collagen precursors. As for proteoglycans [10], this eﬀect
was seen independently of the expected selectivity for one
PPAR isotype although maximal inhibition was observed for
rosiglitazone. The contribution of PPARα and PPARγ was
conﬁrmed by the selective reversion of the inhibitory eﬀect
of Wy14643 by GW6471 and of rosiglitazone by GW9662,
respectively. These data were consistent with the inhibitory
eﬀect of PPARγ agonists on epithelial cells proliferation and
ability to synthesize collagens in response to TGF-β [28–30].
Our data was more surprising for PPARα agonists since
Wy14643 was unable to suppress the inducing eﬀect of
TGF-β1 on collagen type I in pulmonary myoﬁbroblasts
[30]. As these data were obtained from diﬀerent cell types
(myoﬁbroblasts versus chondrocytes) and for diﬀerent col-
lagens (type I versus type II), it might be suggested that
this discrepancy could reﬂect cell speciﬁcities and/or result
from a diﬀerent regulation of collagen genes by TGF-β.
However, a regulatory role of PPAR α on the synthesis
of extracellular matrix components is supported indirectly
by the enhanced matrix formation found in the kidney
of PPAR α-deﬁcient mice developing diabetes [31]. At thePPAR Research 7
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Figure 4: Eﬀects of synthetic PPAR agonists on TIMP-1 production and changes of global MMPs (-1, -2, -3, -7, and -9) and speciﬁc MMP-
13 activities induced by TGF-β1 in rat chondrocytes. Chondrocytes, embedded in alginate beads (5.104 cells per bead), were exposed to
Wy14643 (100μM), GW501516 (100nM), or rosiglitazone (10μM) for 2h before stimulation with TGF-β1 (10ng/mL), in the presence or
absence of PPAR agonists, for 72h. (a) Global activity of MMPs (-1, -2, -3, -7, and -9) in culture supernatants by ﬂuorimetric assay (n = 6);
(b) Activity of MMP-13 in culture supernatants by speciﬁc ﬂuorimetric assay (n = 6); (c) TIMP-1 protein levels in culture supernatants by
ELISA (n = 3). Data were expressed as mean ± SEM and statistically signiﬁcant diﬀerences from the control were indicated as ∗P<. 05 and
from TGF-β1-treated cells as #P<. 05.
concentrationused,Wy14643wasthoughttoinhibitcollagen
synthesis by a PPAR α-a n dγ-dependent mechanism in
hepatic stellate cells [24], but such dual inhibitory eﬀect
was not supported by our reversion study with the PPAR α
antagonist GW6471. Our data were less clear for PPARβ/δ
since the inhibitory eﬀect of GW501516 on TGF-β1-induced
expression of type II collagen was reversed by the PPAR γ
antagonist GW9662. It could not be excluded that GW9662
behaved as a moderate PPAR β/δ antagonist in our culture
system [32]. Data are lacking on the contribution of PPAR
β/δ to the synthesis of extracellular matrix components, but
its expression was found to be regulated antagonistically by
TGF-β1 and inﬂammatory cytokines during wound healing
[33], suggesting that it could interfere with matrix turnover
as a result of signalling cross-talks. Taken together, our data
demonstrated that activation of any PPAR isotype reduced
the stimulatory eﬀect of TGF-β1 on collagen synthesis,
in the context of a broader suppressive eﬀect on the
synthesisofcartilagespeciﬁccomponents.AstypeIIcollagen
concentration was shown to mediate part of the stimulatory8 PPAR Research
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Figure 5: Selective reversion of anti-TGF-β1 potency of PPAR agonists on collagens’ deposition in rat chondrocytes. Chondrocytes,
embedded in alginate beads (5.104 cells per bead), were pretreated for 2h with Wy14643 (100μM), GW501516 (100nM), or rosiglitazone
(10μM), in the presence or absence of synthetic PPARα (GW6471, 10μM) or synthetic PPARγ (GW9662, 10μM) antagonists, before
stimulation with 10ng/mL TGF-β1 for 72h. (a) Collagens’ deposition in the extracellular matrix (cell-associated matrix) after coloration of
representative sections of beads (n = 6, G: 400X) by Sirius red after 72h. (b) Measurement of Sirius red staining of the representative section
of beads using NIH/Image software (n = 4). Data were expressed as mean ± SEM and statistically signiﬁcant diﬀerences from the control
were indicated as ∗P<. 05; from TGF-β1-treated cells as #P<. 05; from “TGF-β1+agonists”-treated cells as §P<. 05.
eﬀect of TGF-β1 on its own expression [34], PPAR agonists
might reduce extracellular matrix synthesis through direct
and indirect mechanisms in chondrocytes.
The presence of multiple TIMPs including TIMP-1 [35]
or TIMP-3 [36] in normal human synovium and TIMP-
2i na d u l tc a r t i l a g e[ 35] may protect the integrity of the
extracellular matrix. The in vivo increase in TIMP-3 and
TIMP-1 messengers may be mediated by factors in joints
such as serum, IL-1β,a n dT G F - β1, which also induce them
in vitro [37, 38]. TIMP-1 and TIMP-3 may be beneﬁcial
for normal joints; however, their increase in human or
bovine arthritic joint has been associated with pathological
remodelling [36].
Concomitantly to the increase of TIMP-1, TGF-β1h a s
been shown to inhibit several MMP expression or activity.
Indeed, TGF-β1 decreased MMP-1 and MMP-3 in human
normal cartilage [39]. The clinical manifestations of an
imbalance between TIMPs and tissue degrading enzymes
are evident in a variety of pathological states, in which
inadequate cartilage remodelling is obvious [40, 41]. In our
report, we found that MMP-3 mRNA expression and MMP
(-1, -2, -3, -7, and -9) activities were decreased, while a slight
downregulation of MMP-13 mRNA expression or activity
was observed. Taken together, TGF-β1a p p e a r st ob ea n
anticatabolic factor in normal rat chondrocytes cultured in
alginate beads by decreasing MMP expressions, suggesting
the important role of this growth factor in extracellular
matrix- (ECM-) cartilage synthesis and turnover. Our data
showed that PPAR ligands diﬀerentially regulated MMP
expression or activities in presence or absence of TGF-β1.
In the presence of PPAR agonists, the inhibitory potency
of TGF-β1 on MMP activities and mRNA levels was shown
to be completely reversed by rosiglitazone and GW501516,
while being unaﬀected by Wy14643. Nevertheless, in our
experimental conditions, the basal MMP activities were
decreased signiﬁcantly by Wy14643, as well as the basal
mRNA levels for MMP-3 and MMP-13, demonstrating that
the regulation of expression or activities of MMP were
dependent on the selectivity proﬁle of each PPAR agonist.
Taken together, only Wy14643 appeared to protect cartilagePPAR Research 9
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Figure 6: Selective reversion of anti-TGF-β1p o t e n c yo fP P A R
agonists on type II collagen mRNA expression in rat chon-
drocytes. Chondrocytes, embedded in alginate beads (5.104 cells
per bead), were pretreated for 2h with Wy14643 (100μM),
GW501516 (100nM), or rosiglitazone (10μM), before stimulation
with10ng/mLTGF-β1for48h.NormalizedcollagentypeIImRNA
levels were quantiﬁed by real-time PCR (n = 4). Data were
expressed as mean ± SEM and statistically signiﬁcant diﬀerences
from the control were indicated as ∗P<. 05; from TGF-β1-treated
cells as #P<. 05; from “TGF-β1+agonists”-treated cells as §P<
.05.
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Figure 7: Selective reversion of anti-TGF-β1p o t e n c yo fP P A R
agonists on global MMP (-1, -2, -3, -7, and -9) activity in rat
chondrocytes. Chondrocytes, embedded in alginate beads (5.104
cells per bead), were pretreated for 2h with Wy14643 (100μM),
GW501516 (100nM), or rosiglitazone (10μM), in the presence or
absence of synthetic PPARα (GW6471, 10μM) or synthetic PPARγ
(GW9662, 10μM) antagonists, before stimulation with 10ng/mL
TGF-β1 for 72h. Global MMP (-1, -2, -3, -7, and -9) activities was
evaluated by ﬂuorigenic assays in culture supernatants (n = 4).
Data were expressed as mean ± SEM and statistically signiﬁcant
diﬀerences from the control were indicated as ∗P<. 05, from TGF-
β1-treated cells as #P<. 05, and from “TGF-β1+agonists”-treated
cells as §P<. 05.
directly from collagens degradation by reducing MMP’
expression or activities.
Our data demonstrate for the ﬁrst time that PPAR
agonists reduce TGF-β1-induced changes in collagen
metabolism and TIMP-1/MMPs balance. These agonists
modulate ECM turnover and inhibit chondrocyte activities
crucial for collagen biosynthesis, and display a diﬀerent
inhibitory proﬁle depending on selectivity for PPAR
isotypes, especially for MMP. Our data might suggest
that PPAR agonists as Wy14643 might be beneﬁcial for
preventing the progression of joint pathologies by protecting
extracellular matrix components from catabolic factors.
PPAR agonists showed anti-inﬂammatory and anticatabolic
properties in animal models of adjuvant-induced arthritis
where PPAR agonists reduced synovial inﬂammation,
while preventing cartilage destruction or loss in bone
mineral density [42]. A recent in vitro study demonstrated
an inhibition of the expression of PPAR γ in human
osteoarthritic cartilage and its downregulation by IL-1β via
a mechanism involving activation of MAPKs (p38 and JNK)
and NFκB signalling pathways, suggesting that upregulation
of PPAR γ might be beneﬁcial in the context of preventing
osteoarthritis [43]. Physiological ﬁndings of inﬂammatory
experimental models of osteoarthritis demonstrated that
30mg/day pioglitazone, a PPAR α>γagonist [10, 42],
ameliorated most aspects of joint lesions of the femoral
condyles rather than those of the tibial plateaus [22, 44].
Although the exact reason of the diﬀerence in eﬀectiveness
of pioglitazone remain unclear, the eﬀect of this agonist
was correlated with a reduction of inﬂammation while
preventing cartilage erosion via inhibition of synthesis or
activity of catabolic factors, such as MMP (-1 & -13) or
ADAMTS-5 [44]. In the present work, we demonstrated
that PPAR agonists (Wy14643) are capable to inhibit mRNA
expression or activity of MMP-3 & 13 and global MMP
activity through a PPAR-independent mechanism pathway.
Although upregulation of PPAR γ h a sb e e nr e p o r t e dt ob e
beneﬁcial in the context of preventing osteoarthritis and
arthritis, the PPAR-independent mechanism contribution
to the anticatabolic potency of the PPAR agonists may be
in good agreement with the absence of any relationship
between the polymorphism PPARγ or the severity of
osteoarthritis [45]. Furthermore, since clinical data reported
that rheumatoid arthritis patients treated with PPAR
agonists for type 2 diabetes or dyslipidemia are paradoxically
suﬀering from osteoarthritis [46], the proof of concept that
PPARagonistshavetherapeuticalrelevancemaybeneﬁtfrom
an epidemiological study of joint lesions in patients with
advanced osteoarthritis treated for long periods of time with
PPAR α>γ(pioglitazone) or PPAR α (ﬁbrate, Wy14643)
agonists. In that case, we hope that the present work could
be taken into consideration in the establishment of new
targeted therapies or protocols dedicated to the treatment
of advanced arthritic and/or osteoarthritic patients with less
safety concern.
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